secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004057
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne reports $642M cash, positive DYNE-101 DM1 data, H1 2026 submission path
----------------------------------------------------------------------------

- Preliminary cash, equivalents, and marketable securities ~$642M as of Dec 31, 2024 (unaudited).
- DYNE-101 in DM1: 6.8 mg/kg Q8W dose showed robust splicing correction at 3 months and sustained functional improvements.
- DYNE-101 safety: 855 doses administered, >72 patient-years follow-up; no related serious TEAEs.
- Plans ~32-patient Registrational Expansion Cohort for DYNE-101 in mid-2025; U.S. accelerated approval submission targeted H1 2026.
- DYNE-251 for DMD exon 51: FDA supports dystrophin as surrogate endpoint; data from 20 mg/kg cohort expected late 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525004057/0001193125-25-004057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525004057/d909941d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer